Lucid Diagnostics (LUCD) announced its intention to offer shares of common stock through an underwritten public offering. Canaccord Genuity and BTIG are acting as joint bookrunners of the offering and Maxim Group is acting as co-manager of the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LUCD:
- Positive Outlook for Lucid Diagnostics: Medicare Coverage and Clinical Support Boost EsoGuard’s Market Potential
- Lucid Diagnostics price target raised to $2.50 from $2 at BTIG
- Positive Outlook on Lucid Diagnostics’ EsoGuard Test Driven by Clinician Support and Potential Medicare Coverage
- Positive Outlook on Lucid Diagnostics Driven by EsoGuard’s Clinical Efficacy and Potential Medicare Coverage
- Lucid Diagnostics Earnings Call: Optimism Amid Challenges